Polycystic Ovary Syndrome Drugs Market Growth

P e r s i s t e n c e M a r k e t R e s e a r c h
across the globe. Leading market players are also investing significantly in developing new
branded drugs to treat PCOS, owing to an anticipated high rise in the global patient population.
The demand for branded PCOS drugs is likely to increase significantly during the forecast
period.
Request For Table of Content Here @ http://www.persistencemarketresearch.com/marketresearch/polycystic-ovarian-syndrome-drugs-market/toc
The global PCOS drugs market is segmented based on Drug Class into Oral Contraceptives,
Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase
Inhibitors, and Diuretics. The contraceptive drug class segment is projected to register a CAGR
of 5.4% over the forecast period. Oral contraceptives are generally the preferred first line therapy
for the treatment of PCOS as they are easily available as OTC drugs. The insulin sensitizing
agent segment is expected to register a CAGR of 4.8% over the forecast period. About 70% of
PCOS patients are overweight and are in the category of possible candidates for type 2
diabetes. As a result, insulin sensitizing agents are the widely prescribed drugs for the treatment
of PCOS today. In terms of value, the oral contraceptives and insulin sensitizing agents drug
class segments are collectively expected to remain the dominant and most attractive segments
over the forecast period.
The global PCOS drugs market is segmented based on Distribution Channel into Hospital
Pharmacies, Drug Stores/OTC, E-Commerce, and Fertility Clinics. The hospital pharmacies
segment is likely to lead the global PCOS drugs market in terms of revenue growth and is
estimated to be valued at US$ 575.4 Mn by the end of 2024. In terms of value, the drugs
stores/OTC segment is estimated to account for 27.0% share of the overall market by the end of
2016.
On the basis of region, the market has been segmented into North America, Latin America,
Europe, Asia Pacific, and the MEA. The North America market is expected to emerge as the
dominant market for polycystic ovary syndrome drugs owing to a high diagnosis rate and
increasing adoption of prescription drugs. North America is estimated to dominate the PCOS
drugs market with maximum value share of the overall market by the end of 2016. The presence
of well-established pharmaceutical companies in North America as well as a relatively high
instance of patients being diagnosed in hospitals for PCOS is a major driver for market growth.
The market in the Asia Pacific region is expected to register the highest CAGR of 5.5% over the
forecast period. Significant increase in healthcare services spending along with rapid economic
Global Polycystic Ovary Syndrome (PCOS) Drugs Market 2016-2024